Document is current
Any future updates will be listed below
-
Authors
Ozawa, Michinobu
Naito, Sei
Makinoshima, Hideki
Ito, Hiromi
Tsuya, Atsushi
Narisawa, Takafumi
Fukuhara, Hiroki
Takai, Yuki
Ushijima, Masaki
Yagi, Mayu
Nishida, Hayato
Tsuchiya, Norihiko
-
Funding
Funding for this research was provided by:
Japan Society for the Promotion of Science (JP22K16814)
- License Information
-
More Information
Article History
Received: 10 April 2024
Accepted: 10 July 2025
First Online: 22 August 2025
Declarations
:
: This study was approved by the Ethics Committee of Yamagata University based on the Declaration of Helsinki (approval number: 2019 − 311) and written informed consent for the use of clinical samples was obtained from all patients.
: Not applicable.
: Sei Naito received honoraria from Pfizer Japan Inc., Merk biopharma Japan Inc., Bristol Meier’s squibb Japan Inc., Ono Pharma, MSD Japan, and Eisai Co. as their sponsored speaker. Norihiko Tsuchiya received honoraria from Pfizer Japan Inc. Janssen, Novartis, Ono, Bayer, Sanofi, Takeda Pharm, Bristol-Myers Squibb Japan, and Astelas Pharma., as their sponsored speaker and research funds from Pfizer Japan Inc. and Eisai outside the submitted work. The other authors have declared that no conflict of interest exists.
